Journal profile · Medicine-Endocrinology, Diabetes and Metabolism
Diabetes Therapy
ISSN 1869-6953 · eISSN 1869-6961 · Springer Healthcare · ENGLAND · 12 issues per year · Founded 2010
Diabetes Therapy: CAS Zone 3 · Medicine (2025 upgraded edition); impact factor 4.18; fully open access; APC about USD 7,400; median 60 days to acceptance (94 articles, last 24 months); 147 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Diabetes Therapy is published by Springer Healthcare and is in Zone 3 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Diabetes Treatment and Management, Diabetes Management and Research and Diabetes, Cardiovascular Risks, and Lipoproteins, together about 54.4% of its articles. Its main subfields are Endocrinology, Diabetes and Metabolism. (generated from OpenAlex topic counts and CAS ranking data)
Aims and Scope Diabetes Therapy is an international, peer reviewed, rapid-publication (peer review in 2 weeks, published 3–4 weeks from acceptance) journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of therapeutics and interventions (including devices) across all areas of diabetes and related disorders, including obesity and metabolic syndromes therapies. Studies relating to diagnostics and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged. The journal is of interest to a broad audience of healthcare professionals and publishes original research, reviews, communications and letters. The journal is read by a global audience and receives submissions from all over the world. Diabetes Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of all scientifically and ethically sound research. Rapid Publication The journal’s rapid publication timelines aim for a peer review decision within 2 weeks of submission. If an article is accepted it will be published online 3-4 weeks from acceptance. Please note that for any steps outside of our standard publication processes, such as multiple rounds of peer review or article proofs, or non-standard copyright requests, this may delay publication beyond these timelines. These rapid timelines are achieved through the combination of a dedicated in-house editorial team, who closely manage article workflow, and an extensive Editorial and Advisory Board who assist with rapid peer review. This allows the journal to support the rapid dissemination of research, whilst still providing robust peer review. Combined with the journal’s open access model this allows for the rapid and efficient communication of the latest research and reviews, allowing the advancement of clinical therapies. Personal Service The journal’s dedicated in-house editorial team offer a personal “concierge service” meaning that authors will always have a personal point of contact able to update them on the status of their man
From the journal's Aims & Scope
Research area (LetPub): Medicine-Endocrinology, Diabetes and Metabolism
Editorial board by country: 7 in mainland China (about 5%); most named United Kingdom 20, United States 19, India 14, Italy 13, Japan 10 (136 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Diabetes Treatment and ManagementMedicine24%
- Diabetes Management and ResearchMedicine20.2%
- Diabetes, Cardiovascular Risks, and LipoproteinsMedicine10.3%
- Hyperglycemia and glycemic control in critically ill and hospitalized patientsMedicine8.1%
- Diabetes Management and EducationMedicine5.8%
- Pancreatic function and diabetesMedicine4.9%
- Metabolism, Diabetes, and CancerBiochemistry, Genetics and Molecular Biology4.2%
- Diabetes and associated disordersBiochemistry, Genetics and Molecular Biology3.8%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Endocrinology & Metabolism | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Endocrinology & Metabolism | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Endocrinology & Metabolism | Zone 4 |
Top journal: noReview journal: no
Database indexing
SCIEScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
EmbaseCASPublisher website
Other: Google Scholar, EBSCO, ProQuest, Dimensions, CNKI, Baidu, Naver, OCLC, Portico, CLOCKSS, Semantic Scholar
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 4.18LetPub ·
- Impact factor (publisher) 2025
- 4.2Publisher website ·
- 5-year impact factor (publisher) 2025
- 3.7Publisher website ·
- CiteScore 2026-06
- 5.7LetPub ·
- SJR 2026-06
- 1.14LetPub ·
- SNIP 2026-06
- 1.14LetPub ·
- h-index
- 25LetPub ·
- h-index
- 77OpenAlex ·
- i10-index
- 935OpenAlex ·
- 2-year mean citedness
- 5.57OpenAlex ·
- Self-citation rate
- 4.8%LetPub ·
- Share of gold OA articles
- 99.77%LetPub ·
Volume
- Articles per year
- 130LetPub ·
- Downloads per year (publisher) 2025
- 1,900,000Publisher website ·
Articles by year OpenAlex count · 1,919 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 86 | 86 | 62 |
| 2025 | 147 | 147 | 562 |
| 2024 | 163 | 163 | 1,581 |
| 2023 | 159 | 159 | 1,744 |
| 2022 | 153 | 153 | 1,625 |
| 2021 | 207 | 207 | 3,789 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
60 daysMedian, submission to acceptance · P25–P75 39 days – 102 days
- Acceptance to online
- median 26 days (94 articles)
- Submission to online
- median 91 days
- Sample
- 94 articles with submission and acceptance dates (267 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 6 weeksLetPub ·
- Submission to first decision
- 1 daysPublisher website ·
- Acceptance to publication
- 28 daysPublisher website ·
- Peer review
- Anonymous peer reviewLetPub
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessOpenAlex
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 7,400 / EUR 5,750 / GBP 4,900 | — | — | |
| LetPub | EUR 5,500 / USD 6,850 / GBP 4,700 | Yes | — | |
| Publisher website | EUR 5,950 / USD 7,675 / GBP 5,120 | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Policy excerpts from the journal's websiteLicense & copyright, Open access, Peer review, Preprints
- License & copyright Copyright
Diabetes Therapy's content is published open access under the Creative Commons Attribution-Noncommercial License, which allows users to read, copy, distribute, and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited. The author assigns the exclusive right to any commercial use of the article to Springer. For more information abou…
Source ↗Publisher website ·- Open access Open access publishing
To find out more about publishing your work Open Access in Diabetes Therapy, including information on fees, funding and licences, visit our Open access publishing page.
Source ↗Publisher website ·- Peer review Peer Review Process
Upon submission, manuscripts are assessed by the editorial team to ensure they fit within the aims and scope of the journal and are also checked for plagiarism. All suitable submissions are then subject to a comprehensive single-blind peer review. Reviewers are selected based on their relevant expertise and publication history in the subject area. The journal has an extensive pool of editorial and…
Source ↗Publisher website ·- Preprints Preprints
We encourage posting of preprints of primary research manuscripts on preprint servers, authors’ or institutional websites, and open communications between researchers whether on community preprint servers or preprint commenting platforms. Posting of preprints is not considered prior publication and will not jeopardize consideration in our journals. Please follow the link for further information on…
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Springer Healthcare
- Country or region
- ENGLAND
- Language
- English
- Frequency
- 12 issues per year
- Founded
- 2010
- ISSN
- 1869-6953
- Electronic ISSN
- 1869-6961
- Latest issue on the website
- Volume 17, Issue 9 (September 2026)
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
- Author guidelines ↗LetPub
- Aims & Scope ↗LetPub
- Special issues ↗Publisher website
- Peer review process ↗LetPub
- Editorial board ↗LetPub
FAQ
Frequently asked questions about Diabetes Therapy
What CAS zone is Diabetes Therapy in?
In the 2025 upgraded edition of the CAS Journal Ranking, Diabetes Therapy is in Zone 3 of Medicine, and in Zone 4 of the minor category Endocrinology & Metabolism. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Diabetes Therapy?
The latest impact factor listed by LetPub is 4.18; CiteScore 5.7, h-index 77.
How long does peer review take at Diabetes Therapy?
Based on the dates recorded on 94 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 60 days (interquartile range 39–102 days); authors report an average review time of about 6 weeks. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Where are the editorial board members of Diabetes Therapy based?
Of the 136 board members whose country the journal's board page names, 7 (about 5%) are in mainland China; the countries named most often are United Kingdom (20), United States (19) and India (14). Counted from the institutions listed on the board page; for reference only.
Which databases index Diabetes Therapy?
According to LetPub and DOAJ records, Diabetes Therapy is indexed in SCIE, Scopus and DOAJ. The journal's website also lists Embase and CAS; that list has not been checked against each database.
Is Diabetes Therapy open access, and what is the APC?
Diabetes Therapy is a fully open-access journal. APC about USD 7,400.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .